Skip to main content
. 2021 Feb 15;29(6):2053–2066. doi: 10.1016/j.ymthe.2021.02.015

Figure 4.

Figure 4

CTNNb1 mRNA expression for cells treated with Centyrin-siRNA conjugates against multiple antigens

(A) LNCAP cells were treated with 200 nM nonbinding Centyrin-siRNA conjugate (neg Cent-siRNA_1) or PSMA-binding Centyrin-siRNA conjugate (PSMA Cent-siRNA_1) against CTNNb1 for 72 h, and mRNA was detected by qRT-PCR. (B) A431 cells were treated with 125 nM nonbinding Centyrin-siRNA conjugate (neg Cent-siRNA_1) or EpCAM-binding Centyrin-siRNA conjugate (EpCAM Cent-siRNA_1) for 72 h. (C) H929 cells were treated with 175 nM non-binding Centyrin-siRNA conjugate or BCMA Centyrin-siRNA conjugate for 72 h, and CTNNb1 mRNA was assessed by qRT-PCR. Significant CTNNb1 mRNA knockdown was observed only with treatment with targeted siRNA conjugates but not non-binding Centyrin-siRNA conjugates. n = 4 per group. Data plotted as mean ± SEM. ∗p < 0.05 versus untreated controls.